Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP-2 ADC + toripalimab for resectable locally advanced oral squamous cell carcinoma
ChiCTR2600129814Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan, sacituzumab tirumotecan and toripalimab in Oral Mucosal Carcinoma, sponsored by Shanghai East Hospital. Primary endpoint: Major pathological response (MPR) rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecansacituzumab tirumotecantoripalimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600129814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129814.